Meet PSI at the Mycoses Study Group Education & Research Consortium (MSGERC) 2026 Biennial Meeting!
PSI CRO is attending MSGERC 2026 to discuss the operational realities shaping invasive fungal infection trials, including enrollment complexity, global site strategy, and execution predictability in rare and high-risk infectious disease studies.
Sponsors developing therapies for invasive fungal infections face significant pressure around patient identification, endpoint integrity, and rapid startup across geographically dispersed centers. PSI is running 2/3 of all industry antifungal clinical trials and has contributed to the FDA antifungal approval landscape through decades of infectious disease operational expertise.
At MSGERC 2026, our team will discuss how sponsors are using AI-enabled feasibility, site intelligence, and experienced infectious disease teams to maintain enrollment momentum and execution quality in complex antifungal programs.
Attending team members:
- Cecilia Dignani
Director Medical Monitoring & Consulting
Related resources:
Blog: ESCMID 2026: Developments in sepsis, antimicrobial resistance, antifungals, and immunotherapies
Case Study: Driving antifungal trial success with global expertise
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
White Paper: The operational reality of agentic AI in phase 2-3 trials
